Bristol's Fibrotic Game Plan: Promedior Buy Hinges On Phase II Data
This article was originally published in Scrip
Already very active in deal-making for fibrotic disease companies and candidates in the past year, Bristol-Myers Squibb ponied up $150m in upfront cash on Aug. 31 for an option to acquire Promedior Inc. and its mid-stage biologic for myelofibrosis (MF) and idiopathic pulmonary fibrosis (IPF).
You may also be interested in...
The deal, which includes up to $1bn for milestones, gives Roche Promedior’s PRM-151, a Phase III-ready asset for IPF that has also completed a Phase II study in myelofibrosis and could be effective in a broad range of fibrotic diseases.
License deal for preclinical S-365598 continues longstanding R&D relationship between ViiV and stakeholder Shionogi, which also developed dolutegravir and cabotegravir.
Speakers on a panel about health care deal-making discussed the influx of capital into biotech during the past two years, how that has impacted deal-making and whether those changes will last.